AstraZeneca Plc said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for its drug to treat a type of severe asthma, potentially speeding up its development and review.
The drug, Tezepelumab, is developed by British-listed AstraZeneca and its U.S. partner Amgen Inc. (Reporting by Nivedita Balu in Bengaluru; Editing by Sai Sachin Ravikumar)